Exclusive Summary

• - Aligned with global guidelines as a first-line oral antiviral for high-risk non-severe COVID-19, using the standard 0.15 g/0.1 g co-pack, 5-day regimen.
• - Distributable in MPP-licensed or patent-free jurisdictions, fitting public tenders and emergency stockpiles.
• - Typically >90% cheaper per treatment than originator, enabling scale-up in national and hospital procurement and private insurance.
• - Very large at-risk population (hundreds of millions globally), with recurrent waves driving steady replenishment demand.
• - Differentiate via stable API supply, calendar-style co-pack, robust DDI management support, and strong compliance credentials.

Asset Materials

Contact Us for Full Materials